financetom
Business
financetom
/
Business
/
Meta closes deal to buy up to 3.9 million carbon credits in Latin America
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Meta closes deal to buy up to 3.9 million carbon credits in Latin America
Sep 22, 2024 11:17 PM

SAO PAULO (Reuters) - Facebook owner Meta agreed to buy up to 3.9 million carbon offset credits from Brazilian investment bank BTG Pactual's forestry arm through 2038, the companies said on Wednesday in a statement.

They did not disclose the value of the deal. The average price for forestry carbon offsets last week was $4.22 per credit, according to data provider Allied Offsets. That could value the deal at up to $16 million based on that pricing.

Carbon offsets allow companies to offset greenhouse gas emissions by paying for actions to cut emissions elsewhere to meet corporate climate goals. Each credit represents a reduction of one metric ton of carbon dioxide emissions.

Under the long-term contract signed by Meta and BTG Pactual Timberland Investment Group (TIG), the owner of Facebook and Instagram agreed to buy 1.3 million carbon credits, with options to purchase an additional 2.6 million credits.

Meta said the deal is its largest carbon removal transaction from a single project and is part of its commitment to reach net zero emissions across its value chain in 2030.

The credits were generated by BTG Pactual TIG's forest restoration projects in Latin America, where it has planted more than 7 million seedlings, according to the statement.

In June, TIG announced the sale of 8 million carbon credits to Microsoft in the largest-ever transaction of such credits worldwide.

The deals from Microsoft and Meta come even though demand for offsets broadly stalled last year.

Companies including food giant Nestle and fashion house Gucci have reduced their buying of credits amid widespread doubts that they served to reduce emissions.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Live Nation probing Ticketmaster hack amid user data leak concerns
Live Nation probing Ticketmaster hack amid user data leak concerns
Jun 3, 2024
SAN FRANCISCO (Reuters) - Live Nation Entertainment said on Friday it was investigating a data breach at its Ticketmaster unit that it discovered on May 20, the latest in a string of high-profile corporate hacks in the past year. In a filing with the U.S. Securities and Exchange Commission, Live Nation said it found unauthorized activity in a third-party cloud...
Intellia Therapeutics' NTLA-2002 Phase 1 Study Observes 98% Mean Reduction in Monthly Attack Rate
Intellia Therapeutics' NTLA-2002 Phase 1 Study Observes 98% Mean Reduction in Monthly Attack Rate
Jun 3, 2024
05:22 AM EDT, 06/03/2024 (MT Newswires) -- Intellia Therapeutics ( NTLA ) said Sunday that it observed a 98% mean reduction in monthly attack rate in the phase 1 portion of its ongoing phase 1/2 study of NTLA-2002. The study is evaluating the safety and activity of NTLA-2002 in adults with Type I or Type II hereditary angioedema, or HAE,...
Boeing executives unlikely to be charged over 737 MAX crashes, source says
Boeing executives unlikely to be charged over 737 MAX crashes, source says
Jun 3, 2024
New York (Reuters) - Boeing ( BA ) executives are unlikely to be criminally charged over fatal crashes in 2018 and 2019 that killed 346 people as the statute of limitations has likely passed, U.S. Justice Department officials told victims' family members in a meeting. Details were corroborated by a person familiar with the gathering on Friday and correspondence reviewed...
GSK Interim Analysis of Phase III Trial for Blood Cancer Therapy Shows Promise
GSK Interim Analysis of Phase III Trial for Blood Cancer Therapy Shows Promise
Jun 3, 2024
05:18 AM EDT, 06/03/2024 (MT Newswires) -- GSK (GSK) said on Sunday that an interim analysis of the phase III trial evaluating its experimental therapy belantamab mafodotin, in combination with pomalidomide plus dexamethasone, showed promise as a second-line and later treatment for a type of blood cancer. The study showed statistically significant and clinically meaningful improvement in progression-free survival for...
Copyright 2023-2025 - www.financetom.com All Rights Reserved